Kinaset Therapeutics

Kinaset Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Boston, Massachusetts, focused on developing inhaled therapeutics to address significant unmet medical needs in severe respiratory diseases. The company's lead program, KN-002, is a novel inhaled kinase inhibitor designed to treat all patients with severe asthma regardless of the underlying cause of inflammation, offering a non-invasive anti-inflammatory approach that delivers the drug directly to the site of inflammation in the lung while minimizing systemic exposure. This mechanism distinguishes Kinaset from biologics that target specific inflammatory pathways, potentially enabling broader patient eligibility. Kinaset raised a $40M Series A and a $103M oversubscribed Series B financing in early 2026 to advance KN-002 toward clinical trials. The Series B was backed by EQT Life Sciences among other investors. The company was co-founded by Robert Clarke (CEO) and Roger Heerman (CBO), both of whom bring extensive experience in drug development and delivery. Kinaset is advancing KN-002 through IND-enabling studies with a goal of initiating clinical trials in patients with severe asthma.